Literature DB >> 21480559

Bevacizumab and heart failure.

Rebecca Kirk.   

Abstract

Entities:  

Year:  2011        PMID： 21480559     DOI： 10.1038/nrclinonc.2011.11

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Congestive heart failure risk in patients with breast cancer treated with bevacizumab.

Authors:  Toni K Choueiri; Erica L Mayer; Youjin Je; Jonathan E Rosenberg; Paul L Nguyen; Georges R Azzi; Joaquim Bellmunt; Harold J Burstein; Fabio A B Schutz
Journal:  J Clin Oncol       Date:  2011-01-04       Impact factor: 44.544
  1 in total
  4 in total

1.  Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer.

Authors:  Haruka Chino; Yosuke Amano; Yasuhiro Yamauchi; Jun Matsuda; Norihiko Takeda; Goh Tanaka; Daiya Takai; Takahide Nagase
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

2.  Elevated Soluble Fms-Like Tyrosine Kinase-1 and Placental-Like Growth Factor Levels Are Associated With Development and Mortality Risk in Heart Failure.

Authors:  Muhammad Hammadah; Vasiliki V Georgiopoulou; Andreas P Kalogeropoulos; Malory Weber; Xi Wang; Michael A Samara; Yuping Wu; Javed Butler; W H Wilson Tang
Journal:  Circ Heart Fail       Date:  2015-12-23       Impact factor: 8.790

3.  Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.

Authors:  Ian S Patten; Sarosh Rana; Sajid Shahul; Glenn C Rowe; Cholsoon Jang; Laura Liu; Michele R Hacker; Julie S Rhee; John Mitchell; Feroze Mahmood; Philip Hess; Caitlin Farrell; Nicole Koulisis; Eliyahu V Khankin; Suzanne D Burke; Igor Tudorache; Johann Bauersachs; Federica del Monte; Denise Hilfiker-Kleiner; S Ananth Karumanchi; Zoltan Arany
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

Review 4.  Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.

Authors:  Ali Raufi; Abdul Shukkur Ebrahim; Ayad Al-Katib
Journal:  Cancer Manag Res       Date:  2013-08-27       Impact factor: 3.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.